Vikas Lifecare 2026: ₹200 Cr raise, cap to ₹300 Cr

Board clears a fresh capital-raising plan

Vikas Lifecare Limited’s board of directors approved a set of proposals aimed at strengthening the company’s financial position and supporting expansion. The approvals came at a board meeting held on April 11, 2026 at the company’s registered office. The meeting ran from 11:00 A.M. to 12:10 P.M., according to the disclosed details. The core proposal is to raise up to ₹200 crore through a preferential issue of warrants and or equity shares. Alongside the fund raise, the board also approved steps to increase the company’s authorised share capital to ₹300 crore. The company also moved to update its constitutional documents to align governance provisions with the planned capital actions. These proposals will require member approval before implementation.

Preferential issue: size, instruments, and tranches

The fundraising approval is structured as a preferential issuance of warrants and or equity shares for up to ₹200 crore. The issuance may be executed in one or more tranches. The company said the process will follow Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The board has authorised a dedicated Fund Raising Committee to carry out the implementation. This committee is tasked with finalising the allottees and handling execution-related decisions. The issue price will be determined using the applicable SEBI pricing formula. The company has not disclosed the proposed list of investors or the final pricing at this stage. Further details are expected after required approvals and finalisation.

Fund Raising Committee’s role and governance oversight

The board’s decision authorises the Fund Raising Committee to oversee the preferential issue process end to end. That includes procedural steps and final decisions on the identity of allottees. It also includes determination of the issue price in line with SEBI’s prescribed pricing methodology. The company has indicated that the issuance can be completed across multiple tranches, which typically requires coordination on timing and regulatory filings. The committee structure is intended to centralise execution responsibilities rather than routing each operational step through the full board. Any subsequent outcomes and updates are to be disclosed to stock exchanges in line with applicable listing regulations. The company has said additional disclosures will follow once relevant details are finalised.

Authorised share capital to rise to ₹300 crore

To accommodate the planned issuance of new securities, the board approved increasing Vikas Lifecare’s authorised share capital to ₹300 crore. The enhanced authorised capital will consist of equity shares with a face value of Re. 1 each. Increasing authorised capital is a prerequisite for issuing additional shares beyond the current authorised limit. The move also signals that the company wants capacity for future capital requirements beyond the immediate fund raise. As part of this step, the board approved amendments to the Capital Clause in the company’s Memorandum of Association (MOA). These amendments are intended to reflect the new authorised capital limit once approved by shareholders.

MOA and AOA changes: “Further Issue of Capital” clause

In addition to the authorised capital proposal, the board approved amendments to the Articles of Association (AOA). A key change is the insertion of a “Further Issue of Capital” clause. The company said these amendments are designed to align its governing documents with the proposed capital infusion. The stated objective is also to ensure compliance with the Companies Act, 2013. The new clauses will set out procedures for offering shares to existing shareholders and to employees under stock option schemes, as well as to other persons through special resolutions. This is presented as a governance and compliance step linked directly to the company’s capital-raising plan. The company also indicated amendments to both MOA and AOA as part of the overall package.

Shareholder approval via postal ballot and e-voting

The proposals are subject to approval from the company’s members. Vikas Lifecare plans to seek this approval through a postal ballot process. The postal ballot will include an e-voting facility. The company has also appointed a scrutineer to oversee the voting process. After shareholder approval, the company will proceed with the allotment of warrants and or equity shares under the preferential issue. The company has said the process will be conducted with disclosures to the National Stock Exchange (NSE) and BSE Limited. This is to comply with SEBI’s listing regulations and related disclosure requirements.

What the company said the money is for

Vikas Lifecare stated that the capital infusion is intended to fund organic and inorganic growth opportunities. The company also linked the fundraising to business expansion plans and strengthening its overall financial position for future opportunities. The text does not specify business segments, project names, acquisition targets, or a detailed allocation plan. It does, however, frame the fundraising as a strategic step to expand operations and explore new adjacencies. The company also highlighted that pricing for the preferential allotment will follow SEBI’s pricing formula. How effectively the company deploys the new capital toward stated objectives is positioned as an important factor for tracking after the issue is executed.

Key board decisions and process snapshot

Background: earlier capital actions cited in disclosures

The broader set of information around Vikas Lifecare includes earlier preferential and institutional issuance activity. One disclosure noted that the promoter, Mr Vikas Garg, converted 3,45,00,000 warrants into an equal number of equity shares at an issue price of ₹4 per share including a premium of ₹3, after paying the remaining 75% of the issue price. Those warrants were originally allotted in March 2024 with an initial 25% payment at allotment. Another note stated the board approved the allotment of 24.25 crore fully convertible warrants at a preferential price of ₹4 each, convertible within 18 months, based on approvals received earlier. Separately, a fund-raising committee outcome dated January 10, 2024 mentioned allotment of 10,41,65,000 equity shares at the issue price to eligible qualified institutional buyers, with a placement document dated January 10, 2024. These past references provide context that the company has used multiple capital-raising routes, but they are separate from the April 11, 2026 board approvals.

Market disclosures and investor considerations

The company stated it fulfilled its disclosure obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 by informing NSE and BSE about the board meeting outcomes. Any further details, such as the final issue price and identities of allottees, are expected after the committee finalises terms and shareholders approve the proposal. The text also flags that investors should be mindful of the company’s history of net losses and declining profit margins, without providing specific figures in the provided material. In market data cited elsewhere in the provided text, the stock was noted at an intraday high of ₹5.10 versus a previous close of ₹4.97, with a 52-week high of ₹7.92 and 52-week low of ₹3.01, and market cap described as over ₹800 crore. These price-related figures are presented as context points, while the immediate event remains the board-approved fundraising and governance changes.

What to watch next

The next concrete step is the postal ballot outcome, since the preferential issue, authorised capital increase, and MOA-AOA amendments require shareholder approval. After that, investors will look for disclosures on the final issue price, the selected allottees, and the tranche structure. The company has indicated it will make disclosures to NSE and BSE in line with listing and disclosure requirements. Execution will also hinge on adherence to SEBI’s pricing formula and the procedural requirements under the ICDR framework and Companies Act provisions referenced in the approvals. Until those filings are made and approvals received, the April 11, 2026 decisions remain board-level clearances rather than completed transactions.